Making trials matter: pragmatic and explanatory trials and the problem of applicability

被引:352
作者
Treweek, Shaun [1 ,2 ]
Zwarenstein, Merrick [3 ,4 ,5 ]
机构
[1] Univ Dundee, Div Clin & Populat Sci & Educ, Dundee, Scotland
[2] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway
[3] Sunnybrook Hlth Sci Ctr, Ctr Hlth Serv Sci, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada
[4] Inst Clin Evaluat Sci, Toronto, ON, Canada
[5] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada
关键词
RANDOMIZED CONTROLLED-TRIALS; EXTERNAL VALIDITY; COMPLEX INTERVENTIONS; CLINICAL-TRIAL; CARE; EXTENSION; FRAMEWORK; CHILDREN; STROKE; RISK;
D O I
10.1186/1745-6215-10-37
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Randomised controlled trials are the best research design for decisions about the effect of different interventions but randomisation does not, of itself, promote the applicability of a trial's results to situations other than the precise one in which the trial was done. While methodologists and trialists have rightly paid great attention to internal validity, much less has been given to applicability. This narrative review is aimed at those planning to conduct trials, and those aiming to use the information in them. It is intended to help the former group make their trials more widely useful and to help the latter group make more informed decisions about the wider use of existing trials. We review the differences between the design of most randomised trials (which have an explanatory attitude) and the design of trials more able to inform decision making (which have a pragmatic attitude) and discuss approaches used to assert applicability of trial results. If we want evidence from trials to be used in clinical practice and policy, trialists should make every effort to make their trial widely applicable, which means that more trials should be pragmatic in attitude.
引用
收藏
页数:9
相关论文
共 60 条
[1]  
Alford L., 2007, New Zealand Journal of Physiotherapy, V35, P12
[2]  
Altman DG, 1999, BRIT MED J, V318, P1209
[3]  
[Anonymous], SOCIOLOGY IN PRESS
[4]  
[Anonymous], 1995, NEW ENGL J MED, V333, P1581, DOI [10.1056/NEJM199512143332401, DOI 10.1056/NEJM199512143332401]
[5]  
[Anonymous], Public Health, DOI DOI 10.1016/S0033-3506(02)00027-6
[6]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[7]   Use of ramipril in preventing stroke: double blind randomised trial [J].
Bosch, J ;
Yusuf, S ;
Pogue, J ;
Sleight, P ;
Lonn, E ;
Rangoonwala, B ;
Davies, R ;
Ostergren, J ;
Probstfield, J .
BMJ-BRITISH MEDICAL JOURNAL, 2002, 324 (7339) :699-702
[8]   Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: Explanation and elaboration [J].
Boutron, Isabelle ;
Moher, David ;
Altman, Douglas G. ;
Schulz, Kenneth F. ;
Ravaud, Philippe .
ANNALS OF INTERNAL MEDICINE, 2008, 148 (04) :295-309
[9]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[10]   Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease [J].
Coca, Steven G. ;
Krumholz, Harlan M. ;
Garg, Amit X. ;
Parikh, Chirag R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (11) :1377-1384